Related Experiment Videos

Randomized steroid therapy of human kidney transplant rejection

S A Stromstad1, H M Kauffman, D Sampson

  • 1Department of Surgery, Medical College of Wisconsin, Milwaukee.

Surgical Forum
|January 1, 1978
PubMed

Insights

High-dose methylprednisolone bolus therapy did not improve outcomes for acute kidney transplant rejection. The higher dose was linked to increased infections and septic mortality, making it not recommended.

Area of Science:

  • Nephrology
  • Immunosuppression
  • Transplantation

Background:

  • Acute kidney transplant rejection is a significant clinical challenge.
  • Methylprednisolone is a commonly used immunosuppressant in transplantation.

Purpose of the Study:

  • To compare the efficacy of high-dose (30-mg/kg) versus standard-dose (3-mg/kg) methylprednisolone bolus for acute kidney transplant rejection.
  • To evaluate the safety profile of high-dose methylprednisolone, specifically infection rates and septic mortality.

Main Methods:

  • Randomized, double-blind study design.
  • Inclusion of patients experiencing acute kidney transplant rejection.
  • Administration of two different methylprednisolone bolus doses: 30 mg/kg and 3 mg/kg.

Main Results:

  • No statistically significant therapeutic benefit was observed with the 30-mg/kg methylprednisolone bolus compared to the 3-mg/kg bolus.
  • A trend towards increased incidence of infections was noted in the high-dose group.
  • A slight increase in septic mortality was associated with the high-dose methylprednisolone regimen.

Conclusions:

  • High-dose methylprednisolone bolus therapy offers no added therapeutic advantage over standard-dose for acute kidney transplant rejection.
  • The routine use of high-dose methylprednisolone bolus is not recommended due to increased risks of infection and septic mortality.

Related Concept Videos